Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

ACLX - Arcellx, Inc. Stock Price, Fair Value and News

$65.25+2.12 (+3.36%)
Delayed as of 23 Apr 2025, 12:00 pm ET
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

ACLX Price Action

Last 7 days

2.8%

Last 30 days

-8.9%

Last 90 days

-4.1%

Trailing 12 Months

21.4%

ACLX RSI Chart

AugSepOctNovDec2025FebMarApr102030405060708090100

ACLX Valuation

Market Cap

3.5B

Price/Earnings (Trailing)

-32.31

Price/Sales (Trailing)

32.14

EV/EBITDA

-33.6

Price/Free Cashflow

-35.8

ACLX Price/Sales (Trailing)

2024AprJulOct2025Apr2025303540

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ACLX Fundamentals

ACLX Revenue

Revenue (TTM)

107.9M

Rev. Growth (Yr)

-75.83%

Rev. Growth (Qtr)

-41.35%

AprJulOct2024AprJulOct110M120M130M140M150M160M

ACLX Earnings

Earnings (TTM)

-107.3M

Earnings Growth (Yr)

-337.26%

Earnings Growth (Qtr)

-82.01%

2021202220232024-200M-150M-100M-50M

ACLX Profitability

EBT Margin

-97.54%

Return on Equity

-23.6%

Return on Assets

-15.09%

Free Cashflow Yield

-2.79%

ACLX Investor Care

Shares Dilution (1Y)

11.07%

Diluted EPS (TTM)

-2

ACLX Alerts

Revenue Breakdown

As of: Dec 31, 2024
AprJulOct2024AprJulOct10M20M30M40M50M60M
Total
TotalValuePercent

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2024AprJulOct110M120M130M140M150M160M
Net sales
YearQ1Q2Q3Q4
2024131.7M144.7M155.8M107.9M
2023000110.3M
Get all data in R, Python etc through our Historical Stock Data APIs

About Arcellx, Inc.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
 CEO
 WEBSITEhttps://arcellx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES98

Arcellx, Inc. Frequently Asked Questions

What is the ticker symbol for Arcellx, Inc.? What does ACLX stand for in stocks?

ACLX is the stock ticker symbol of Arcellx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcellx, Inc. (ACLX)?

As of Tue Apr 22 2025, market cap of Arcellx, Inc. is 3.47 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACLX stock?

You can check ACLX's fair value in chart for subscribers.

Is Arcellx, Inc. a good stock to buy?

The fair value guage provides a quick view whether ACLX is over valued or under valued. Whether Arcellx, Inc. is cheap or expensive depends on the assumptions which impact Arcellx, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACLX.

What is Arcellx, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 22 2025, ACLX's PE ratio (Price to Earnings) is -32.31 and Price to Sales (PS) ratio is 32.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACLX PE ratio will change depending on the future growth rate expectations of investors.